WHO Recommendations for the production, control and regulation of human plasma for fractionation 2 0 0 2011/05/18 1390/2/28 2015/01/3 1393/10/13 ## ##

Securing Safe Plasma for Fractionation the Duty of any Country 2 0 0 2011/05/182011/05/18 1390/2/28 2015/01/32015/01/3 1393/10/13 ## ##

Pathogen Reduction of Plasma 2 0 0 2011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/3 1393/10/13 ## ##

Plasma Fractionation Industry Project in Turkey: Country’s Experiences 2 0 0 2011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Patients Perspective in Plasma Products (Focus on Hemophilia) 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Clinical application of plasma derived medicines: current situation and future trend 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Access and Rational use of Plasma Protein Therapies (PPTs) 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Hyperimmunes Plasma Procurement and Products 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Quality Assurance and Good Manufacturing Practice in Respect of Plasma Fractionation 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Plasma derived versus biotechnological manufactured medicine 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Making plasma derived medicines available 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Worldwide Supply and Demand of Plasma And Plasma-Derived Medicines 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Plasma Fractionation in Malaysia 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Self Sufficiency In Plasma And Plasma Derived Medicines 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##

Message of President of ISBT to 2nd International Conference on Transfusion Medicine/Plasma Industry in Tehran, Iran, May 10-11, 2011 2 0 0 2011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/182011/05/18 1390/2/28 2015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/32015/01/3 1393/10/13 ## ##